GlaxoSmithKline PLC Q2 2019 Earnings Call Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Kerry Ann Holford - Exane BNP Paribas, Research Division - Analyst : Two questions, please. Firstly, just following up on ViiV. Thinking about the outlook for the remainder of the year. So in the quarter, U.S. sales were down 6%. I wonder, David, if you can talk to how you expect that to evolve in the second half of the year. And in the first half of the year, that equated to just 1% sales growth globally. Are we still expecting ex-U. S. regions to deliver more significant growth to drive that higher? Or are you looking at that remaining similar level for the remainder of the year, 1% growth or so? And then secondly, on Zejula. For Hal, I wonder -- I know you can't give us details on PRIMA, but if we are to say that data can come at ESMO, can you tell us whether or not we will get detailed results by subgroups? And here I'm talking about HRD+ as well as negative. Also interested in any view you may have on how that data could compare to PAOLA-1 for the [abstract] if that is also positive. Can these 2 approaches coexist?